WO2018192590A3 - Stable oral pharmaceutical composition and preparation method therefor - Google Patents

Stable oral pharmaceutical composition and preparation method therefor Download PDF

Info

Publication number
WO2018192590A3
WO2018192590A3 PCT/CN2018/091940 CN2018091940W WO2018192590A3 WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3 CN 2018091940 W CN2018091940 W CN 2018091940W WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical composition
pharmaceutically acceptable
method therefor
oral pharmaceutical
Prior art date
Application number
PCT/CN2018/091940
Other languages
French (fr)
Chinese (zh)
Other versions
WO2018192590A2 (en
Inventor
高慧燕
张利锋
陈见阳
Original Assignee
浙江京新药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江京新药业股份有限公司 filed Critical 浙江京新药业股份有限公司
Publication of WO2018192590A2 publication Critical patent/WO2018192590A2/en
Publication of WO2018192590A3 publication Critical patent/WO2018192590A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Disclosed are a stable oral pharmaceutical composition and a preparation method therefor. The composition contains an effective amount of a compound having the structure shown in formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, the pharmaceutically acceptable carrier comprising a polymer having a melting point, glass transition temperature and softening temperature of less than 180°C, the mass ratio of the polymer with respect to the compound having the structure shown in formula I or the pharmaceutically acceptable salt thereof being more than 1.
PCT/CN2018/091940 2017-04-21 2018-06-20 Stable oral pharmaceutical composition and preparation method therefor WO2018192590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710264635.6 2017-04-21
CN201710264635.6A CN107007559B (en) 2017-04-21 2017-04-21 Stable oral pharmaceutical composition and preparation method thereof

Publications (2)

Publication Number Publication Date
WO2018192590A2 WO2018192590A2 (en) 2018-10-25
WO2018192590A3 true WO2018192590A3 (en) 2018-12-20

Family

ID=59446978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/091940 WO2018192590A2 (en) 2017-04-21 2018-06-20 Stable oral pharmaceutical composition and preparation method therefor

Country Status (2)

Country Link
CN (1) CN107007559B (en)
WO (1) WO2018192590A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230883A (en) * 1996-09-24 1999-10-06 伊莱利利公司 Coated particle formulation
CN1178662C (en) * 1995-03-24 2004-12-08 伊莱利利公司 Oral 2 -methyl -thieno -benzodiazepine formulation
CN101189001A (en) * 2005-02-15 2008-05-28 伊兰制药国际有限公司 Aerosol and injectable formulations of nanoparticulate benzodiazepine
CN101827597A (en) * 2007-08-20 2010-09-08 伊沃泰克神经科学有限责任公司 Treatment of sleep disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2189759T3 (en) * 1999-05-12 2003-07-16 Hoffmann La Roche DERIVATIVES OF IMIDAZOIACEPINA.
US20090054412A1 (en) * 2007-08-20 2009-02-26 John Alan Kemp Treatment of Sleep Disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178662C (en) * 1995-03-24 2004-12-08 伊莱利利公司 Oral 2 -methyl -thieno -benzodiazepine formulation
CN1230883A (en) * 1996-09-24 1999-10-06 伊莱利利公司 Coated particle formulation
CN101189001A (en) * 2005-02-15 2008-05-28 伊兰制药国际有限公司 Aerosol and injectable formulations of nanoparticulate benzodiazepine
CN101827597A (en) * 2007-08-20 2010-09-08 伊沃泰克神经科学有限责任公司 Treatment of sleep disorders

Also Published As

Publication number Publication date
CN107007559B (en) 2020-05-15
WO2018192590A2 (en) 2018-10-25
CN107007559A (en) 2017-08-04

Similar Documents

Publication Publication Date Title
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3835296A4 (en) Ketoamide compound and preparation method, pharmaceutical composition, and use thereof
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY196328A (en) New (Hetero)Aryl-Substituted-Piperidinyl Derivatives, A Process For Their Preparation And Pharmaceutical Compositions Containing Them
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
BR112013025519A2 (en) pharmaceutical composition
MX2021006697A (en) Hair growth composition and method.
BR112012029517A2 (en) fragrance formulations, manufacturing methods and articles comprising them.
MX2021002220A (en) Crystalline form of lorlatinib free base.
EA200900282A1 (en) APPLICATION OF POLYOLS FOR OBTAINING SUSTAINABLE POLYMORPHIC FORMS OF RIFAXIMINE
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
EA200702589A1 (en) 2,6-quinoline derivatives, methods of their production and their use
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
PH12018500378B1 (en) Novel annelated phenoxyacetamides
AU2017262586A1 (en) Improved drug formulations
MX2020005478A (en) Sulfonamide compounds and use thereof.
WO2018192910A3 (en) Process for making an anti-soiling coating composition and a coating made therefrom
MX2020005564A (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylis oquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof.
MX2015016429A (en) Cxcr7 receptor modulators.
WO2018097603A3 (en) Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
EP3760195A4 (en) Composition comprisng 2,3-butanediol as active ingredient
MX2021014680A (en) Benzotriazole derivative.
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2018192590A3 (en) Stable oral pharmaceutical composition and preparation method therefor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18787390

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18787390

Country of ref document: EP

Kind code of ref document: A2